Compare Citius Pharmaceuticals Inc (CTXR) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Wynn Resorts, Limited — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Wynn Resorts, Limited trades at $75.32 (market cap $7.75B). The key difference: Wynn Resorts, Limited is far larger — about 569× Citius Pharmaceuticals Inc's market cap, and Wynn Resorts, Limited pays a 1.33% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Wynn Resorts, Limited for 76 Days on average.
| CTXR | WYNN | |
|---|---|---|
Market Cap | $13.62M | $7.75B |
Volume | 132,438 | 2,243,813 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $133.09 |
52-Week Low | $0.48 | $74.97 |
Typical Hold Time | 17 Days | 76 Days |
Enterprise Value | $3.79M | $17.99B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Wynn Resorts (WYNN) trades at $75.24, up 0.36% with bearish technical signals from moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but showing margin pressure in U.S. operations. Revenue growth is driven by Macau strength, while significant capital expenditures for new projects in the UAE create cash flow challenges. Analyst consensus remains strongly bullish with a $132.36 price target despite recent earnings volatility and high debt levels.
Investment outlook balances strong Macau recovery against rising capex risks. The stock offers 76% upside to consensus target but faces execution risks on new projects and persistent debt burden. Near-term catalysts include Q3 earnings and UAE project developments, while margin compression and economic sensitivity remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
